user

Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma

被引：2
|
作者：
Dong, Renshun [1 ,2 ,3 ]
Wang, Tianci [1 ,2 ,3 ]
Dong, Wei [1 ,2 ,3 ,4 ,5 ,6 ]
Zhu, He [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Qiumeng [1 ,2 ,3 ,4 ,5 ]
Liang, Huifang [1 ,2 ,3 ,4 ,5 ,6 ]
Chen, Xiaoping [1 ,2 ,3 ,4 ,5 ,6 ]
Zhang, Bixiang [1 ,2 ,3 ,4 ,5 ,6 ]
Zhang, Xuewu [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430030, Hubei, Peoples R China
[2] Hubei Key Lab Hepatopancreato Biliary Dis, Wuhan 430030, Hubei, Peoples R China
[3] Hubei Prov Clin Med Res Ctr Hepat Surg, Wuhan 430030, Hubei, Peoples R China
[4] Minist Educ, Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
[5] Chinese Acad Med Sci, NHC Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
[6] Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2024年 / 173卷
基金：
中国国家自然科学基金;
关键词：
PTPRE inhibitor; Hepatocellular carcinoma; Sorafenib; Organoid; OPEN-LABEL; PLUS; ATEZOLIZUMAB; BEVACIZUMAB; METABOLISM; MYC;
D O I：
10.1016/j.biopha.2024.116366
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Hepatocellular carcinoma (HCC) has a poor prognosis, and the efficacy of current therapeutic strategies is extremely limited in advanced diseases. Our previous study reported that protein tyrosine phosphatase receptor epsilon (PTPRE) is a promoting factor in HCC progression. In this study, our objective was to evaluate the treatment effect of PTPRE inhibitors in different HCC preclinical models. Our results indicated that the PTPRE inhibitory compound 63 (Cpd-63) inhibited tumor cell proliferation, migration, and HCC organoid growth. Mechanism research revealed that Cpd-63 could inhibit the expression of MYC and MYC targets by inhibiting the activation of SRC. Additionally, we found that Cpd-63 could improve the response of sorafenib in HCC cells. In conclusion, we demonstrated that the PTPRE inhibitors represented a potential therapeutic agent for HCC management.
引用
收藏
页数：11
相关论文
共 50 条
  • [1] IN VITRO AND IN VIVO STUDY OF PI-103 AND SORAFENIB ON INHIBITION OF HEPATOCELLULAR CARCINOMA PROLIFERATION AND TUMOR PROGRESSION
    Gedaly, Roberto
    Angulo, Paul
    Hundley, Jonathan
    Daily, Michael F.
    Chen, Changguo
    Evers, Mark
    [J]. HEPATOLOGY, 2011, 54 : 1306A - 1306A
  • [2] Pharmacological inhibition of PIM1 suppresses tumor progression and enhances chemosensitivity in hepatocellular carcinoma
    Leung, Ming Sum
    Chan, Kwan Shuen
    Lo, Cheuk Lam
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E368 - E368
  • [3] Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
    Lin, Hsiao-Hui
    Feng, Wen-Chi
    Lu, Li-Chun
    Shao, Yu-Yun
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    [J]. CANCER LETTERS, 2016, 381 (01) : 58 - 66
  • [4] Hepatocellular Carcinoma Sorafenib: Tumor Volume as a predictive Value for the Response to Therapies?
    Rukavina, Marion
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2014, 52 (09):
  • [5] Knockdown of PKMYT1 is associated with autophagy inhibition and apoptosis induction and suppresses tumor progression in hepatocellular carcinoma
    Wu, Fangnan
    Tu, Chaoyong
    Zhang, Kun
    Che, Hanyang
    Lin, Qiaomei
    Li, Zhuokai
    Zhou, Qingyun
    Tang, Bufu
    Yang, Yang
    Chen, Minjiang
    Shao, Chuxiao
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 640 : 173 - 182
  • [6] Sorafenib Inhibition of Hepatic Stellate Cell Proliferation in Tumor Microenvironment of Hepatocellular Carcinoma: A Study of the Sorafenib Mechanisms
    Zhi-min Geng
    Rajiv Kumar Jha
    Bo Li
    Chen Chen
    Wen-zhi Li
    Jian-bao Zheng
    Lin Wang
    Sha Huanchen
    [J]. Cell Biochemistry and Biophysics, 2014, 69 : 717 - 724
  • [7] Sorafenib Inhibition of Hepatic Stellate Cell Proliferation in Tumor Microenvironment of Hepatocellular Carcinoma: A Study of the Sorafenib Mechanisms
    Geng, Zhi-min
    Jha, Rajiv Kumar
    Li, Bo
    Chen, Chen
    Li, Wen-zhi
    Zheng, Jian-bao
    Wang, Lin
    Sha Huanchen
    [J]. CELL BIOCHEMISTRY AND BIOPHYSICS, 2014, 69 (03) : 717 - 724
  • [8] REDUCED DOSE AND DURATION OF SORAFENIB TREATMENT ARE ASSOCIATED TO TUMOR PROGRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Ponziani, F. R.
    Annichiarico, B. E.
    Siciliano, M.
    Barone, C.
    Basso, M.
    Cesario, V.
    Campanale, M.
    Caracciolo, G.
    Garcovich, M.
    Zocco, M.
    Gigante, G.
    Rinninella, E.
    Sarno, G.
    Di Rienzo, T. A.
    D'Aversa, F.
    Gasbarrini, G.
    Gasbarrini, A.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S65 - S66
  • [9] The role of insulin degrading enzyme in gender disparity of hepatocellular carcinoma progression and sorafenib response
    Pan, Yu
    Xia, Shunjie
    Xu, Junjie
    Cai, Xiujun
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S646 - S646
  • [10] Regorafenib but not sorafenib suppresses ERK signaling in human hepatocellular carcinoma acquiring sorafenib resistance
    Hashiba, Tomomi
    Yamashita, Taro
    Okada, Hikari
    Hayashi, Takehiro
    Yoshida, Mariko
    Sunagozaka, Hajime
    Honda, Masao
    Kaneko, Shuichi
    [J]. HEPATOLOGY, 2016, 64 : 248A - 248A
12345